In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene.
about
Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingDNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinomaOver-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancerElevated expression of Rad51 is correlated with decreased survival in resectable esophageal squamous cell carcinomaHigh-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patientsBortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer.A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts.Design of potent inhibitors of human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a chimera peptide.RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cellsFusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells.Targeting abnormal DNA double strand break repair in cancerRad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cellsNimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair.Targeting the homologous recombination pathway by small molecule modulatorsRad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.Treatment Outcome and Prognostic Molecular Markers of Supratentorial Primitive Neuroectodermal Tumors.Ca2+ improves organization of single-stranded DNA bases in human Rad51 filament, explaining stimulatory effect on gene recombination.Polymorphism within the distal RAD51 gene promoter is associated with colorectal cancer in a Polish population.Role of radiotherapy in the treatment of gliomas.Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines.FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.Use of the Rad51 promoter for targeted anti-cancer therapyErlotinib and concurrent chemoradiation in pretreated NSCLC patients: radiobiological basis and clinical resultsDNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells.DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients.Targeting homologous recombination-mediated DNA repair in cancer.Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells.The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinomaFrom chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells.DNA repair after irradiation in glioma cells and normal human astrocytes.DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.Biomarkers in radiation oncology.DNA-repair gene variants are associated with glioblastoma survival.[Clinical developments for the EGFR-TKI combined with radiotherapy in advanced non-small cell lung cancer].The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer.
P2860
Q26863501-947825D0-395C-4B95-B6DA-989613B08D22Q28138134-A720079B-7C57-42F3-A156-41159892F33EQ28138609-390E388C-2147-45A2-8185-95C35C7D3490Q28242915-3A55AC5D-9C37-46BF-B1B5-3682CA98CA30Q28256642-D79D10AD-106C-4BB0-9ED4-83527EF46A4AQ33798624-16EEC6D2-309A-44AC-8A01-7828D2A458ABQ33815545-E2F6DA7D-E0FE-4779-A069-5B679EE4C6DAQ33817458-67180BD8-C17E-4608-8408-3663A6EFE01BQ34048608-2FA280F6-A614-4025-B062-011ED97E25FDQ34273832-A6FA8967-5B88-4EA4-9D22-8A4AD0A32E71Q34281241-25E075AB-1B9D-4E7B-A7D6-E0EBBC9F915AQ34348322-B7BCF0D7-0534-4387-A0D7-FF78FDB17D7FQ34457557-229E65D9-70DA-443B-AB40-CA46C226FA9EQ34977354-67473DD2-1371-4658-A278-455490F2767BQ35142705-253A73B1-F440-4DCE-821D-603BBC021C26Q35173054-17825B71-C64C-45AD-B34E-A84F488F07F9Q35750271-84F9510D-E2C2-4101-8C76-10A123A31F8EQ35847139-DB738A3B-60E4-41D6-9CFE-E6D37FDF2A16Q35988515-E676D816-2177-4C7F-BCC7-A76AE4C7652DQ36008107-585DCD96-C912-4F02-ACFC-54575D38B475Q36261964-5AB6D6DA-7E6D-449D-8BD4-4FF5690C7D47Q36307807-CA956BDE-55D7-4B01-99FB-8103C5848B8DQ36616430-D175FB92-6F7B-45A3-85FB-273A5BD02FCFQ36803405-5F907D4E-24AA-4B83-9191-EF3DABBA3307Q37081622-65C4CE18-F247-470B-95C5-D94AE86819FBQ37105715-5E6FFBC5-C610-4D08-8889-0286F2A57094Q37229934-D80E377C-8F66-4178-A008-1FF6099601B2Q38097536-845E31F7-E7A3-45AC-8CEA-CE285042982EQ38184667-B2B6BD98-CE8B-4C1D-914A-1A70C54182BEQ38302961-077C21AB-B3E6-41AE-BA62-883D8D661C75Q38719535-EC69B5ED-50AB-47B1-B2FB-050B00FD51B0Q39041541-B126EA8F-1D65-459A-B751-A593A8F4463EQ39406857-3087ED54-BB53-467F-BC7A-1B9EFEA25E5CQ40092752-245C48F7-E76D-4E21-A4AD-362881508C90Q40215417-C0BEF2C6-630D-43DE-86AB-166143525DE5Q43947658-A8B45B12-A2C8-4E42-91D8-49B4C889AB5DQ47567437-1990265D-4D13-4698-9B33-1068D4285B47Q48827117-8B350769-6C74-41B0-B1AD-27530C8C7958Q53238870-54D9C5CD-02F8-427D-80A7-93B752B3A784Q54186992-77253B6A-6871-4A7E-BFFB-1BDF7C3A98F6
P2860
In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
In vitro and in vivo potentiat ...... inhibition of the RAD51 gene.
@en
type
label
In vitro and in vivo potentiat ...... inhibition of the RAD51 gene.
@en
prefLabel
In vitro and in vivo potentiat ...... inhibition of the RAD51 gene.
@en
P2093
P356
P1476
In vitro and in vivo potentiat ...... inhibition of the RAD51 gene.
@en
P2093
P304
P356
10.1006/BBRC.1998.8440
P407
P577
1998-04-01T00:00:00Z